Naiyer Rizvi named director of thoracic oncology at NewYork-Presbyterian/Columbia University Medical Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NAIYER RIZVI was named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center.

Rizvi comes from Memorial Sloan Kettering Cancer Center, where he was an attending physician and focused on thoracic immunotherapy.

He has authored or co-authored more than 60 peer-reviewed papers, books and book chapters, and currently sits on the editorial board of OncoImmunology.

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login